Navigation Links
Immtech Investor Conference Call Scheduled for February 11, 2008
Date:2/6/2008

NEW YORK, Feb. 6 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (Amex: IMM) will have an investor conference call on Monday, February 11, 2008, at 4.30 PM (ET) to discuss its financial results for the quarter ended December 31, 2007 and to present an update on the Company's scientific and clinical progress. Investors and interested parties in the U.S. are invited to join the call by dialing (888) 338-8374 and callers outside the U.S. should call (706) 902-3163. The User Access Code is # 2167994. To register, please call no later than 10 minutes prior to the scheduled start of the call. A recording of the conference call will be available on the Company's website (http://www.immtechpharma.com) from February 12, 2008 to February 29, 2008.

About Immtech Pharmaceuticals, Inc.

Immtech Pharmaceuticals, Inc. ("Immtech") is a pharmaceutical company working to commercialize drugs to treat infectious diseases and is expanding its targeted markets by applying its proprietary pharmaceutical platform to treat other disorders. Immtech has advanced clinical programs that include new oral treatments for pneumocystis pneumonia (PCP), trypanosomiasis (HAT or African sleeping sickness), malaria and a well defined, expanding library of compounds targeting drug-resistant Gram-positive bacteria, fungal infections, Hepatitis C and other serious diseases. Immtech holds the exclusive worldwide licenses to certain patents, patent applications and technology for products derived from its proprietary pharmaceutical platform. For additional information, please visit Immtech's website at http://www.immtechpharma.com.

This press release contains forward-looking statements regarding Immtech's business, including the future prospects for PCP. Except for historical information, the matters discussed in this press release are forward-looking statements and are subject to risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to the following: (i) Immtech's ability to develop commercially viable products; (ii) Immtech's ability to achieve profitability; (iii) Immtech's ability to retain key personnel; (iv) the ability of Immtech's scientists and collaborators to discover new compounds; (v) the availability of additional research grants; (vi) Immtech's ability to obtain regulatory approval of its drug candidates, including PCP; (vii) the success of Immtech's clinical trials; (viii) Immtech's dependence upon and contractual relationship with partners; (ix) Immtech's ability to manufacture or to contract with a third party to manufacture its drug candidates at reasonable costs; (x) Immtech's ability to protect its intellectual property; (xi) competition and alternative technologies; (xii) Immtech's ability to obtain reimbursement from third party payers for any product it commercializes; and (xiii) Immtech's potential exposure to significant product liability.

Additional risks are discussed in Immtech's current filings with the Securities and Exchange Commission. Although Immtech believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. The forward-looking statements are made as of the date of this press release, and Immtech undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.


'/>"/>
SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine
2. Immtech to Present at The Bank of Montreal Healthcare Conference
3. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
4. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
5. Media Advisory - Oncolytics Biotech Inc. to Present at Bio CEO & Investor Conference
6. PharmAthene to Present at the BIO CEO & Investor Conference 2008
7. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
8. Iomai CEO to Speak at BIO CEO & Investor Forum on Feb. 12
9. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
10. Rigel to Present at BIO CEO & Investor Conference
11. Cell Therapeutics, Inc. (CTI) to Present at 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... , ... The Academy of Model Aeronautics is thrilled to announce a new ... through Labor Day 2016. Bill Chaffee’s Boeing P-12B will be exhibited thanks to a ... first place for Senior Scale Model at the 1930 National Airplane Model League of ...
(Date:5/27/2016)... , ... May 27, 2016 , ... PBI-Gordon Corporation is ... and Ornamental Products. , In his 15-year career with PBI-Gordon, Dave has served in ... where he was integral in the development and launch of many of PBI-Gordon’s most ...
(Date:5/27/2016)... -- At present, the Biotech sphere is in ... that volatility is what makes this industry interesting to consider. ... Corp. (NASDAQ: SNTA ), CTI BioPharma Corp. (NASDAQ: ... ), and Heat Biologics Inc. (NASDAQ: HTBX ). ... for these stocks at: http://www.activewallst.com/register/ ...
(Date:5/26/2016)... 26, 2016 Q BioMed Inc. (OTCQB: ... be a featured presenter at the 5th Annual Marcum MicroCap ... York City at the Grand Hyatt Hotel. ... BioMed Inc. CEO, is scheduled to begin at 11a.m ET ... business strategy, recent developments and outline milestones for the balance ...
Breaking Biology Technology:
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
Breaking Biology News(10 mins):